Sepsis Diagnostics Market worth $613.9 Million by 2023 | Key Players bioMérieux, Danaher, Roche, Abbott, Becton, Dickinson and Company
[193 Pages Report] The global sepsis diagnostics market was valued at USD 367.9 Million in 2017 and is expected to reach USD 613.9 Million by 2023, at a CAGR of 9.1% during the forecast period.
According to the new market research report "Sepsis Diagnostics Marketby Technology (Microbiology, Molecular Diagnostic, Immunoassay, Biomarkers), Product (Blood Culture Media, Instruments), Method (Automated), Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End-User - Global Forecast to 2023", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
Don’t miss out on business opportunities in Sepsis Diagnostics Market.
Speak to our analyst and gain crucial industry insights that will help your business grow:https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=92673155
Factors such as rising prevalence of sepsis across the globe, increasing geriatric population, growing government initiatives for creating sepsis awareness, and high incidence of hospital-acquired infections are expected to drive the demand for sepsis diagnosis during the study period.
This report broadly segments the market into technology, product, pathogen, method, test type, end user, and region.
Based on technology, the market is segmented into microbiology, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2017, the microbiology segment accounted for the largest share of the sepsis diagnostic market. This share can be attributed to the low cost of microbiology techniques and the wide use of blood culture methods for the diagnosis of sepsis.
On the basis of products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. The blood culture media segment is estimated to command the largest share of the global market in 2018. The large share of this segment can be attributed to the increasing use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis.
Based on methods, the sepsis diagnostic market is categorized into two segments, namely, conventional diagnostics and automated diagnostics. The automated diagnostics segment is expected to grow at the highest CAGR from 2018 to 2023. Accurate detection of positive blood cultures, quick turnaround time, and reduced risk of contamination is contributing to the growth of this segment.
The report covers the sepsis diagnostics market across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the market in 2018, due to the growing prevalence of sepsis, fast adoption of high-end sepsis diagnostics devices, and rising government support for sepsis-related research.
The major players of the market are bioMérieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany).
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly